5. PORTABLE MEDICAL DEVICE
WHICH IDENTIFIES HUMAN BLOODTYPE
FAST
Blood-type
detection in 3mins
PORTABLE
To be used whenever
and wherever
INEXPENSIVE
80% cheaper
than other lab machines
DECREASES
O- dependency
6. FEATURES
Minimum process time (min.)
≈ 11
≈ 30
≈ 26
>9
> 9
≈ 25 3
Emergency use
Portability
# Of samples
20
224
N/A
96
48
42 1
Price $ 95.000 + $ 100.000 + $ 100.000 + $ 100.000 $ 16.000
According to the WHO, the price range for a ABO blood type system can have an average price
range of $ 115.000 to $ 225.000
DIFFERENTIATORS
“With the mission to transform transfusion diagnostics through the provision of the comprehensive automated testing solutions, improving patient outcomes, delivering
major efficiencies”.
The healthcare transfusion market needs development and disruption. Quotient is changing transfusion diagnostics with a transformative and disruptive diagnostics
platform at laboratory/hospital environment while CRIAM wants to do it in a portable way. Quotient already secured the needed investment and is now considered a
visionary at this space.
OTHER:
7. DEVICE AS A PLATFORM
HIV . BRUCELLA . LYME DISEASE . SYPHILLIS . MONONUCLEOSIS . MENINGITIS
9. HEALTHCARE MARKET GOVERNMENTS
MILITARY NGO’S
POTENTIAL MARKET
More than
170.000
Hospitals and
Medical institutions
More than
100.000
Ground ambulance
Vehicles worldwide
$4B>
11. PRICES:
• Cartridge (wholesale) - $ 12
• Cartrdige (retail) - $ 16
PRICE STRATEGY:
• Device (wholesale) - $ 11.200
• Device (retail) - $ 16.000
• Or no cost depending on annual cartridge
commitment
When a new disease detection is developed, it will be possible to update the
device with disease algorithms – through OTA or USB – with an annual based
fee.
Device
Retail revenue stream
DISTRIBUTOR MARGIN:
35%
Cartridges
Recurrent revenue stream
DISTRIBUTOR MARGIN:
33%
We aim to adopt a Nespresso approach by emphasizing
recurrent revenue stream from the cartridges leveraging on
economy of scale.
Software Updates
Not included in this business case
BUSINESS MODEL
13. DR. BAKRI DR. MACHADO DR. SOUSADR. CARVALHO
OUR
ADVISORS
AND
PARTNERS
14. PROJECT RECOGNITION
1st place
Microsoft Imagine
Cup Worldwide
1st place
“Nação Inovadora”
Top 15
HAX Acceleration Program
(sponsored by
Johnson & Johnson)
Showcasing at CES
in LA
Top 8
Health Startups at
Pioneers ’17
Showcasing at
MUC Summit in
Munich and
WebSummit ’16
and ‘17
Top 5
Startup Package Austria
(Out – Dec ‘17)
Top 10
Showcasing at Health
Pioneers (Oct ‘17)
H2020 Seal of
Excellence
&
Portuguese Grant
($340.000)
EU Top 50
Nov’ 17
15. HOW SUCCESS
LOOKS LIKE IN 18
MONTHS
Month 1
• CMO on-board
Month 2
Month 3
• Start of CE Mark and FDA process (regulatory filing)
Month 4
• Distribution Agreements signed (top 5 markets)
Month 5
• 10 final devices ready (for blood-type and subtype)
Month 9
• Ready to manufacture (outsourcing scale-up);
• Scientific publications in the Top Science Magazines
Month 10
• Distribution Agreement/Market Access (EU/EMEA)
Month 12
• Market expansion – Asia PAC – Market Access
Month 14
• Market expansion – UAE – Market Access
Month 18
• US launch – Market
• Access Diseases
• Pipeline R&D
16. Ready for commercialization
Pre-clinical trials performed
Scientific papers published
Partnership with Birmingham Bio-Hub
US Company in Delaware (Q1 2018)
SOSV commitment for the round
Industrialization R&D Marketing HRIP Validation
+ + + + $1.9M
FUNDING NEEDS
